Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the combination of its experimental drug fostrox with Japan partner Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC). The trial focuses on patients for whom current first- or second-line treatments have proven ineffective or intolerable.
Disease Stabilization and Good Tolerability Observed
According to the press release, seven out of ten patients receiving the combination therapy for more than three months have seen their disease stabilized. This indicates a significant response rate in the study population. Moreover, the therapy has demonstrated good tolerability, even among patients with impaired liver function resulting from HCC.
Advancing to the Next Phase of Development
In light of these encouraging results, Medivir is preparing to advance the treatment to the next phase of development. This move underscores the company’s commitment to exploring new and effective treatment options for patients with advanced HCC, a disease with limited treatment options.-Fineline Info & Tech
